Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Slow-Release "Jelly" Novel Drug Deliverer

Published: Wednesday, January 30, 2013
Last Updated: Wednesday, January 30, 2013
Bookmark and Share
Biomedical engineers have developed a novel method to overcome the major hurdles facing a promising new class of peptide drugs to treat diseases such as diabetes and cancer.

For example, the hormone insulin is a peptide, which regulates the metabolism of carbohydrates in the body and is used as a drug to treat diabetes. There are more than 40 peptide drugs approved for use in humans and more than 650 are being tested in clinical studies.

However, despite their effectiveness, these peptide drugs cannot achieve their full potential for a number of reasons. First, they are rapidly degraded in the blood stream. A second major drawback is their rapid clearance from the body, which requires multiple, frequent injections. Because of this, their concentrations in the blood can rise precipitously right after injection and fall dramatically soon thereafter, causing unwanted side effects for patients.

One popular method to solve this problem involves loading peptide drugs into polymer microspheres that are injected under the skin and slowly degrade and release the peptide drug.   Microsphere-release technology has proven useful, but has many issues related to its manufacture and ease of patient use, the researchers said.

“We wanted to know if we could create a system that does what the polymer microspheres do, but gets rid of the microspheres and is more patient friendly,” said Ashutosh Chilkoti, Theo Pilkington Professor of Biomedical Engineering at Duke’s Pratt School of Engineering.

The new approach involves making a “fusion protein” that consists of multiple copies of a peptide drug fused to a polymer that makes the fusion protein sensitive to body heat. The fusion molecule is a liquid in a syringe but transforms into a “jelly” when injected under the skin.  Enzymes in the skin attack the depot and liberate copies of the peptide, which provides a constant and controllable release of drug over time.

Miriam Amiram, former Chilkoti graduate student and first author on the paper, dubbed the new delivery system POD, for protease-operated depot.

In the latest experiments, published on-line in the journal Proceedings of the National Academy of Science, the researchers fused glucagon-like peptide-1 (GLP-1), a hormone that regulates the release of insulin, with a genetically engineered heat sensitive polymer to create the POD.

“Remarkably, a single injection of the GLP-1 POD was able to reduce blood glucose levels in mice for up to five days, which is 120 times longer than an injection of the peptide alone,” Chilkoti said.  “For a patient with type 2 diabetes, it would be much more desirable to inject such a drug once a week or once a month rather than once or twice a day.

“Additionally, this approach avoids the peaks and valleys of drug concentrations that these patients often experience,” Chilkoti said.

Unlike peptide-loaded microspheres, PODs are also easy to manufacture, as the peptide drug and the heat-sensitive polymer are all made of amino acids, so that they are expressed as one long stretch of amino acids in bacteria.

“Our experiments demonstrate that this new delivery system provides the first entirely genetically encoded alternative to existing peptide drug encapsulation approaches for sustained delivery of peptide drugs,” Chilkoti said.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Protein Structures Assemble and Disassemble On Command
Gene sequences may enable control of building bio-structures.
Wednesday, September 23, 2015
Molecular Tinkering Doubles Cancer Drug’s Efficacy
Researchers have packaged a widely used cancer drug into nanoparticles, more than doubling its effectiveness at destroying tumors.
Thursday, August 06, 2015
Outsmarting HIV With Vaccine Antigens Made to Order
AIDS vaccine researchers may be one step closer to outwitting HIV, thanks to designer antibodies and antigens made to order at Duke University.
Thursday, July 02, 2015
Cancer-Fighting Drugs Might Also Stop Malaria Early
A number of compounds have been identified which could be used to fight malaria.
Wednesday, August 27, 2014
Cancer’s Thirst For Copper Can Be Targeted
Drugs used to block copper absorption for a rare genetic condition may find an additional use as a treatment for certain types of cancer.
Thursday, April 10, 2014
Scientific News
Retractable Protein Nanoneedles
The ability to control the transfer of molecules through cellular membranes is an important function in synthetic biology; a new study from researchers at Harvard’s Wyss Institute for Biologically Inspired Engineering and Harvard Medical School (HMS) introduces a novel mechanical method for controlling release of molecules inside cells.
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
NIH Researchers Identify Striking Genomic Signature for Cancer
Institute has identified striking signature shared by five types of cancer.
CRI Develops Innovative Approach for Identifying Lung Cancer
Institute has developed innovative approach for identifying processes that fuel tumor growth in lung cancer patients.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!